Dr. Llovet on Efficacy of Namodenoson in Child-Pugh B HCC
August 6th 2019Josep M. Llovet, MD, discusses a phase II, double-blind, placebo-controlled trial examining the efficacy and safety of namodenoson, an A3 adenosine receptor agonist, as a second-line treatment for patients with Child-Pugh B advanced hepatocellular carcinoma.
Read More